Purdue Pharma has been granted a patent for using tinostamustine in treating T-cell prolymphocytic leukemia (T-PLL). The patent includes a kit with the drug and instructions for administering it at an effective dosage level for T-PLL treatment. GlobalData’s report on Purdue Pharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Purdue Pharma LP - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Purdue Pharma, Human telomerase RT biomarker was a key innovation area identified from patents. Purdue Pharma's grant share as of February 2024 was 52%. Grant share is based on the ratio of number of grants to total number of patents.

Treatment of t-cell prolymphocytic leukemia using tinostamustine

Source: United States Patent and Trademark Office (USPTO). Credit: Purdue Pharma LP

A recently granted patent (Publication Number: US11918558B2) discloses a kit and pharmaceutical composition for treating T-cell prolymphocytic leukemia (T-PLL). The kit includes tinostamustine or its pharmaceutically acceptable salt in a therapeutically effective amount, along with instructions for administration to patients in need of T-PLL treatment. The dosage level for effective treatment ranges from 0.3 mg/m2 to 300 mg/m2 of the patient's body surface area, providing a specific guideline for healthcare professionals.

Moreover, the pharmaceutical composition described in the patent comprises tinostamustine or its salt in a therapeutically effective amount for treating T-PLL. The dosage level for administration falls within the range of 0.3 mg/m2 to 300 mg/m2 of the patient's body surface area, ensuring the appropriate dosage for effective treatment. Additionally, the composition may include a liquid carrier, specifically polyethylene glycol, and is formulated for intravenous administration, highlighting the specific formulation and route of administration for this innovative treatment option for T-PLL patients.

To know more about GlobalData’s detailed insights on Purdue Pharma, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies